2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 200 | - | - | ||
| 408 | - | - | ||
| 1 404 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenTick tock, is it close now? From having been sparing with superlatives during 2025 until the sale of TREX1 to Gilead to being really forward-leaning and almost on the verge of "bullish" (we are the best at what we do) during q1, Sprint with CEO Emilsson is now back to a slightly more restrained style again. Have they come so far already that it's best not to say too much perhaps? All programs in Sprint's portfolio are more or less ready for agreements/sales, but VRK1, I personally believe, is the program that is being worked on the most on that front. The program was licensed out to Day One in 2023 but was returned after 2 years in 2025, why? The answer came earlier this year as Day One was acquired by French Servier; they simply wanted to streamline their portfolio before the sale, and VRK1 was obviously not for Servier, and the program returned to Sprint. From the q1 report: "During the quarter, we presented strong preclinical proof-of-concept data in the VRK1 program. The results show that VRK1 inhibition provides clear tumor inhibition in models with VRK2-low glioblastoma. This is, to our knowledge, the first time a tumor effect from VRK1 inhibition has been shown in vivo, and it represents an important value uplift for the program. The VRK1 program addresses a very large medical need in one of the most difficult-to-treat cancer areas and represents a clear precision medicine case, well suited for partnership with a global pharmaceutical company." Note the last part: "well suited for partnership with a global pharmaceutical company." Not well suited for partnership with a pharmaceutical company, but explicitly for a GLOBAL pharmaceutical company. Is such a company already at the table? I think so. The Gilead deal was done at the eleventh hour with a dwindling cash reserve, yet they managed to get a really nice upfront. It will be incredibly exciting to see what Johan can do WITHOUT that pressure this time. Both Sprint and Day One have invested a lot of money; they probably want that back already in the upfront. I myself intend to be a shareholder until the milestones start to be paid; that's when the true value emerges, and it's not $40M, which is the current mcap, I promise. However, one can probably guess what another deal would do to the company's value 🤤 An acquisition now would be a disappointment in my book; there's potential here to build something truly big. Sprint's way of developing best-in-class programs is unique, and there will be a scramble in the future to collaborate on the platform. Even though Gilead is a real giant in this context, I believe the next agreement/sale will go to one of the real giants in the USA, or perhaps Switzerland? 😉 I think so then.
·2 päivää sittenI specifically notice that they are toning down agreements, platform collaborations ++ That would mean that they are not in a position to say much about it.·2 päivää sittenAbsolutely. The market is far too hot for all dialogue to be gone. I'm increasingly sensing that the sale of the entire pipeline is in the works, or possibly the sale of the entire company.
·2 päivää sittenThey have a deficit of 13 million for the quarter, and have 108 million left in the bank. Based on previous statements, they can probably land another good deal this year. These are indeed strange times, where one can get both security and potential at such a low price. The pricing of several of these biotech companies is completely crazy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenTick tock, is it close now? From having been sparing with superlatives during 2025 until the sale of TREX1 to Gilead to being really forward-leaning and almost on the verge of "bullish" (we are the best at what we do) during q1, Sprint with CEO Emilsson is now back to a slightly more restrained style again. Have they come so far already that it's best not to say too much perhaps? All programs in Sprint's portfolio are more or less ready for agreements/sales, but VRK1, I personally believe, is the program that is being worked on the most on that front. The program was licensed out to Day One in 2023 but was returned after 2 years in 2025, why? The answer came earlier this year as Day One was acquired by French Servier; they simply wanted to streamline their portfolio before the sale, and VRK1 was obviously not for Servier, and the program returned to Sprint. From the q1 report: "During the quarter, we presented strong preclinical proof-of-concept data in the VRK1 program. The results show that VRK1 inhibition provides clear tumor inhibition in models with VRK2-low glioblastoma. This is, to our knowledge, the first time a tumor effect from VRK1 inhibition has been shown in vivo, and it represents an important value uplift for the program. The VRK1 program addresses a very large medical need in one of the most difficult-to-treat cancer areas and represents a clear precision medicine case, well suited for partnership with a global pharmaceutical company." Note the last part: "well suited for partnership with a global pharmaceutical company." Not well suited for partnership with a pharmaceutical company, but explicitly for a GLOBAL pharmaceutical company. Is such a company already at the table? I think so. The Gilead deal was done at the eleventh hour with a dwindling cash reserve, yet they managed to get a really nice upfront. It will be incredibly exciting to see what Johan can do WITHOUT that pressure this time. Both Sprint and Day One have invested a lot of money; they probably want that back already in the upfront. I myself intend to be a shareholder until the milestones start to be paid; that's when the true value emerges, and it's not $40M, which is the current mcap, I promise. However, one can probably guess what another deal would do to the company's value 🤤 An acquisition now would be a disappointment in my book; there's potential here to build something truly big. Sprint's way of developing best-in-class programs is unique, and there will be a scramble in the future to collaborate on the platform. Even though Gilead is a real giant in this context, I believe the next agreement/sale will go to one of the real giants in the USA, or perhaps Switzerland? 😉 I think so then.
- ·2 päivää sittenI specifically notice that they are toning down agreements, platform collaborations ++ That would mean that they are not in a position to say much about it.·2 päivää sittenAbsolutely. The market is far too hot for all dialogue to be gone. I'm increasingly sensing that the sale of the entire pipeline is in the works, or possibly the sale of the entire company.
- ·2 päivää sittenThey have a deficit of 13 million for the quarter, and have 108 million left in the bank. Based on previous statements, they can probably land another good deal this year. These are indeed strange times, where one can get both security and potential at such a low price. The pricing of several of these biotech companies is completely crazy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 200 | - | - | ||
| 408 | - | - | ||
| 1 404 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 |
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenTick tock, is it close now? From having been sparing with superlatives during 2025 until the sale of TREX1 to Gilead to being really forward-leaning and almost on the verge of "bullish" (we are the best at what we do) during q1, Sprint with CEO Emilsson is now back to a slightly more restrained style again. Have they come so far already that it's best not to say too much perhaps? All programs in Sprint's portfolio are more or less ready for agreements/sales, but VRK1, I personally believe, is the program that is being worked on the most on that front. The program was licensed out to Day One in 2023 but was returned after 2 years in 2025, why? The answer came earlier this year as Day One was acquired by French Servier; they simply wanted to streamline their portfolio before the sale, and VRK1 was obviously not for Servier, and the program returned to Sprint. From the q1 report: "During the quarter, we presented strong preclinical proof-of-concept data in the VRK1 program. The results show that VRK1 inhibition provides clear tumor inhibition in models with VRK2-low glioblastoma. This is, to our knowledge, the first time a tumor effect from VRK1 inhibition has been shown in vivo, and it represents an important value uplift for the program. The VRK1 program addresses a very large medical need in one of the most difficult-to-treat cancer areas and represents a clear precision medicine case, well suited for partnership with a global pharmaceutical company." Note the last part: "well suited for partnership with a global pharmaceutical company." Not well suited for partnership with a pharmaceutical company, but explicitly for a GLOBAL pharmaceutical company. Is such a company already at the table? I think so. The Gilead deal was done at the eleventh hour with a dwindling cash reserve, yet they managed to get a really nice upfront. It will be incredibly exciting to see what Johan can do WITHOUT that pressure this time. Both Sprint and Day One have invested a lot of money; they probably want that back already in the upfront. I myself intend to be a shareholder until the milestones start to be paid; that's when the true value emerges, and it's not $40M, which is the current mcap, I promise. However, one can probably guess what another deal would do to the company's value 🤤 An acquisition now would be a disappointment in my book; there's potential here to build something truly big. Sprint's way of developing best-in-class programs is unique, and there will be a scramble in the future to collaborate on the platform. Even though Gilead is a real giant in this context, I believe the next agreement/sale will go to one of the real giants in the USA, or perhaps Switzerland? 😉 I think so then.
- ·2 päivää sittenI specifically notice that they are toning down agreements, platform collaborations ++ That would mean that they are not in a position to say much about it.·2 päivää sittenAbsolutely. The market is far too hot for all dialogue to be gone. I'm increasingly sensing that the sale of the entire pipeline is in the works, or possibly the sale of the entire company.
- ·2 päivää sittenThey have a deficit of 13 million for the quarter, and have 108 million left in the bank. Based on previous statements, they can probably land another good deal this year. These are indeed strange times, where one can get both security and potential at such a low price. The pricing of several of these biotech companies is completely crazy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 200 | - | - | ||
| 408 | - | - | ||
| 1 404 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 409 238 | 409 238 | 0 | 0 |